On Invalid Date, Intercure (NASDAQ: INCR) reported Q3 2022 earnings per share (EPS) of $0.05, up 475% year over year. Total Intercure earnings for the quarter were $2.04 million. In the same quarter last year, Intercure's earnings per share (EPS) was -$0.01.
On Invalid Date, Intercure (NASDAQ: INCR) reported Q3 2022 revenue of $28.25 million up 46.53% year over year. In the same quarter last year, Intercure's revenue was $19.28 million.
What was INCR's revenue growth in the past year?
As of Q1 2023, Intercure's revenue has grown 95.18% year over year. This is 158.22 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 253.41%. Intercure's revenue in the past year totalled $104.25 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.